Your session is about to expire
← Back to Search
EDP-938 for RSV Infection (RSVTx Trial)
RSVTx Trial Summary
This trial is testing a potential new treatment for people who have had a stem cell transplant and who have developed symptoms of a respiratory infection caused by the RSV virus.
RSVTx Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRSVTx Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 82 Patients • NCT04196101RSVTx Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received a type of stem cell transplant called autologous HCT within the past 6 months, or a different type called allogeneic HCT at any time.
- Group 1: EDP-938
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the status of EDP-938's FDA approval process?
"EDP-938 is still in Phase 2 clinical trials, so there is only limited data supporting its safety."
Are we recruiting individuals who are above the age of 50 for this trial?
"For this particular study, investigators are only recruiting patients that fall between the ages of 16-75. Out of the 939 total clinical trials, 244 were for patients under 18 years old and 695 were for seniors over the age of 65."
Are there still open slots for people who want to participate in this clinical trial?
"That is correct, the online registry shows that this research is currently looking for participants. The trial was originally advertised on July 7th, 2021 and has since been updated October 12th, 2022. They are seeking 200 individuals from 3 different locations."
Is there a limit to the number of people who can join this research project?
"The sponsor, Enanta Pharmaceuticals, Inc. needs to recruit 200 eligible patients from various locations, including Augusta University Medical Center in Augusta, Georgia and Toronto General Hospital in Toronto, Ontario."
Could I take part in this experiment if I qualify?
"This clinical trial is recruiting 200 participants, within the ages of 16 and 75 who currently have respiratory syncytial virus infections. It is important that participants also meet the following criteria: Received an autologous HCT (within 6 months of signing ICF) or an allogeneic HCT (any time) using any conditioning regimen, Absolute lymphocyte count (ALC) <500 cells/ µL in allogeneic HCT recipients. Absolute lymphocyte count (ALC) <300 cells/ µL in autologous HCT recipients., Laboratory confirmed RSV diagnosis from a respiratory sample obtained within 3 days"
Share this study with friends
Copy Link
Messenger